Nippon Shinyaku Co Ltd
TSE:4516
Net Margin
Nippon Shinyaku Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
N
|
Nippon Shinyaku Co Ltd
TSE:4516
|
221.7B JPY |
19%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
680.7B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
362.5B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
196.2B CHF |
20%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
176.4B CHF |
23%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
204.8B USD |
27%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
155.9B GBP |
13%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
128.2B USD |
13%
|
Nippon Shinyaku Co Ltd
Glance View
Nippon Shinyaku Co., Ltd. stands as a beacon in the Japanese pharmaceutical landscape, weaving a story that begins over a century ago. Originally founded to address the medical needs of its society, the company has strategically evolved its focus, channeling its expertise into two main business domains: pharmaceuticals and functional food. As it carved its niche, Nippon Shinyaku harnessed the power of innovation and research to develop drugs that address critical medical needs, especially in oncology, hematology, and rare diseases. This specialization not only strengthens its foothold but also embodies a moral commitment to enhancing patient quality of life, proving profitable as these fields often present less competition but promise high demand and returns. Alongside its pharmaceutical ventures, Nippon Shinyaku has leveraged the burgeoning wellness trend through its functional food segment, offering products that promote health and prevent disease. This dual approach leverages the company's bioscience expertise and diversifies its revenue streams, shielding it from the volatility often seen in the pharmaceutical sector. By making strategic alliances and collaborations, both domestically and overseas, Nippon Shinyaku accelerates its market penetration and expands its international footprint. As it capitalizes on its robust R&D capabilities, the company anchors its success on a fusion of scientific advancement and strategic acumen, crafting a narrative of resilience and adaptability in a rapidly evolving industry.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Nippon Shinyaku Co Ltd's most recent financial statements, the company has Net Margin of 19.4%.
You don't have any saved screeners yet